Categories Earnings, Health Care

Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.

— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.

Regeneron reports Q4 2019 earnings results

— Net product sales were $1.28 billion.

— EYLEA net product sales in the US were $1.22 billion.

— Sanofi and Bayer collaboration revenues were $748 million.

— R&D expenses totaled $683 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Also Read:  MongoDB (MDB) beats Q2 estimates: Infographic

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results

2 thoughts on “Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

Comments are closed.

Top